DE-ESCALATION OF TYROSINE KINASE INHIBITOR THERAPY IS SAFE IN CHRONIC MYELOID LEUKAEMIA IN DURABLE MOLECULAR RESPONSE (>= MR3 FOR >= 12 MONTHS): INITIAL RESULTS IN THE BRITISH DESTINY STUDY

File Description SizeFormat 
75.pdfPublished version56.81 kBAdobe PDFDownload
Title: DE-ESCALATION OF TYROSINE KINASE INHIBITOR THERAPY IS SAFE IN CHRONIC MYELOID LEUKAEMIA IN DURABLE MOLECULAR RESPONSE (>= MR3 FOR >= 12 MONTHS): INITIAL RESULTS IN THE BRITISH DESTINY STUDY
Author(s): Clark, R
Polydoros, F
Apperley, J
Pocock, C
Smith, G
Salim, R
Coffey, T
O'Brien, S
Foroni, L
Copland, M
Item Type: Conference Paper
Publication Date: 1-Jun-2016
Date of Acceptance: 1-Jan-2016
URI: http://hdl.handle.net/10044/1/40113
DOI: http://www.haematologica.org/content/101/s1/1
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation
Start Page: 60
End Page: 60
Journal / Book Title: Haematologica
Volume: 101
Issue: Suppl 1
Sponsor/Funder: Bristol Myers Squibb
National Institute for Health Research
Leuka
Funder's Grant Number: n/a
NF-SI-0611-10275
N/A
Conference Name: 21st Congress of the European Hematology Association
Copyright Statement: DE-ESCALATION OF TYROSINE KINASE INHIBITOR THERAPY IS SAFE IN CHRONIC MYELOID LEUKAEMIA IN DURABLE MOLECULAR RESPONSE (>= MR3 FOR >= 12 MONTHS): INITIAL RESULTS IN THE BRITISH DESTINY STUDY. Haematologica vol. 101 no. s1 60. ©2016 by Ferrata-Storti Foundation/European Hematology Association. All rights reserved.
Keywords: Science & Technology
Life Sciences & Biomedicine
Hematology
Immunology
1102 Cardiovascular Medicine And Haematology
Publication Status: Published
Start Date: 2016-06-09
Finish Date: 2016-06-12
Conference Place: Copenhagen, Denmark
Appears in Collections:Department of Medicine
Faculty of Medicine



Items in Spiral are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons